A single psychedelic dose of psilocybin increases synaptic density and temporarily reduces serotonin 2A receptor density in the pig brain. One day after injection, hippocampal synaptic vesicle protein 2A (SV2A) density was 4.42% higher, while hippocampal and prefrontal cortex 5-HT2AR density dropped by 15.21% to 50.19%. Seven days later, SV2A density remained significantly higher in the hippocampus (+9.24%) and prefrontal cortex (+6.10%), but 5-HT2AR density had returned to baseline. These persistent synaptic changes and acute receptor down-regulation may underlie psilocybin’s antidepressant effects.
Psilocybin, a hallucinogen derived from mushrooms, significantly improved mental health outcomes in 60% of participants with treatment-resistant depression in a recent study involving 200 individuals. This psychedelic influences neurotransmitter receptors, particularly serotonin, which plays a crucial role in mood regulation. Participants reported enhanced emotional well-being and reduced anxiety after just two doses. The findings highlight psilocybin's potential as a groundbreaking tool in medicine and psychology, offering new avenues for treating brain disorders linked to tryptophan and serotonin deficiencies.